AbbVie Inc Stock Moved Up by 3.29% on Feb 12: What Investors Need To Know

Several key factors appear to have contributed to the upward intraday movement in AbbVie's stock on February 12, 2026. The underlying positive sentiment stems significantly from the company's robust financial performance and optimistic future outlook provided earlier in the month.

AbbVie reported its full-year and fourth-quarter 2025 financial results on February 4, 2026, which surpassed analyst expectations for both earnings per share and revenue. More importantly, the company issued strong guidance for full-year 2026, projecting adjusted earnings per share and revenue figures that exceeded consensus estimates, signaling an acceleration in growth. While the shares experienced an initial decline post-earnings, this was subsequently viewed by some analysts as a buying opportunity, given the solid fundamentals.

Following the earnings report, several analysts reiterated positive ratings and raised price targets for AbbVie, indicating strong confidence in the company's pipeline and strategic direction. For instance, Morgan Stanley raised its price target and maintained an "overweight" rating on February 6, 2026. Cantor Fitzgerald similarly reaffirmed an "Overweight" rating with a positive price target on the same day. The consensus analyst rating for AbbVie remained "Buy," with many anticipating double-digit upside.

Furthermore, recent developments concerning AbbVie's product pipeline added to the positive momentum. On February 3, 2026, AbbVie submitted regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for Rinvoq (upadacitinib) for the treatment of non-segmental vitiligo. If approved, Rinvoq would be the first systemic medication for this condition, significantly expanding its market opportunity and reinforcing the strength of AbbVie's immunology portfolio.

On the day of the observed volatility, February 12, 2026, AbbVie took a significant step to address regulatory risk by filing a lawsuit against the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS). This lawsuit challenges the inclusion of Botox in the Medicare drug price negotiation program, with AbbVie arguing that Botox, as a plasma-derived product, should be exempt. This proactive legal action to defend a key revenue-generating product like Botox likely resonated positively with investors, as it demonstrates the company's commitment to protecting its commercial interests against potential pricing pressures. Additionally, reports of increased institutional holdings, such as Savvy Advisors Inc. raising its stake, further underpinned investor confidence in the company's trajectory.

Technically, AbbVie Inc (ABBV) shows a MACD (12,26,9) value of [-0.73], indicating a neutral signal. The RSI at 48.28 suggests neutral condition and the Williams %R at -34.86 suggests oversold condition. Please monitor closely.

AbbVie Inc (ABBV) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is 61.16B, ranking 7 in the industry. The net profit is 4.23B, ranking 14 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as BUY, with an average price target of 247.80, a high of 328.00, and a low of 187.64.

Company Specific Risks:

• AbbVie faces significant legal and regulatory risk from its lawsuit filed February 11, 2026, against the Department of Health and Human Services (HHS) challenging the inclusion of its Botox drug in the Medicare Drug Price Negotiation Program under the Inflation Reduction Act, potentially exposing the company to reduced revenue from mandated price cuts if unsuccessful.
• The company demonstrates diversification challenges as its Oncology and Aesthetics portfolios declined in Q4 2025, raising concerns about its ability to generate sustainable growth beyond its core Immunology segment, particularly in the post-Humira exclusivity era.
• AbbVie's 2026 adjusted EPS guidance excludes acquired In-Process Research and Development (IPR&D) and milestone costs, which were substantial in 2025 (e.g., -$2.76/share for the full year), creating uncertainty and potential downward pressure on future earnings as these unpredictable costs are integral to the company's M&A-driven growth strategy.
• Recent analyst downgrades, such as Wolfe Research moving AbbVie from "Outperform" to "Peer Perform" on January 30, 2026, reflect concerns that the current share price already incorporates anticipated gains from key immunology drugs like Skyrizi and Rinvoq, suggesting limited upside potential without clearer future growth catalysts.